I 
110TH CONGRESS 
1ST SESSION H. R. 2223 
To direct the Director of the Office of National Drug Control Policy, in 
consultation with the Attorney General and the Secretary of Health 
and Human Services, to conduct a study on prescription drug take- 
back programs, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 8, 2007 
Mr. PORTER (for himself and Mr. HELLER of Nevada) introduced the 
following bill; which was referred to the Committee on Energy and Commerce 
A BILL 
To direct the Director of the Office of National Drug Control 
Policy, in consultation with the Attorney General and 
the Secretary of Health and Human Services, to conduct 
a study on prescription drug take-back programs, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. PRESCRIPTION DRUG TAKE-BACK PROGRAMS 
STUDIES. 
(a) STUDY CONDUCTED BY DIRECTOR OF THE OF-
FICE OF NATIONAL DRUG CONTROL POLICY.— 
VerDate Aug 31 2005 
22:28 May 09, 2007
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H2223.IH
H2223
pwalker on PROD1PC71 with BILLS
(1) STUDY REQUIRED.—The Director of the Of-
fice of National Drug Control Policy, in consultation 
with the Attorney General and the Secretary of 
Health and Human Services, shall conduct a study 
on prescription drug disposal programs (in this Act 
referred to as ‘‘take-back programs’’) in which indi-
viduals return unused prescription drugs to phar-
macies or other locations. 
(2) FOCUS
OF
STUDY.—The study required 
under paragraph (1) shall focus on the following: 
(A) The methodology, processes, tech-
nology, and best practices with respect to such 
take-back programs. 
(B) The affects of such take-back pro-
grams on pharmacies. 
(C) Training and infrastructure needed to 
ensure the success of such take-back programs. 
(D) Identifying the number of individuals 
that use current take-back programs. 
(E) Identifying any changes to existing 
laws that would allow for full, nationwide imple-
mentation of such take-back programs. 
(F) Identifying the costs to pharmacies of 
such take-back programs. 
VerDate Aug 31 2005 
22:28 May 09, 2007
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2223.IH
H2223
pwalker on PROD1PC71 with BILLS
(G) Identifying methods by which prescrip-
tion drugs can be tracked after they are surren-
dered at pharmacies and other locations, and 
ways in which the Federal government can en-
sure proper destruction. 
(3) REPORT.—Not later than 12 months after 
the date of the enactment of this Act, the Director 
of the Office of National Drug Control Policy shall 
submit to Congress a report containing the fol-
lowing: 
(A) The findings of the study required 
under paragraph (1). 
(B) Any recommendations with respect to 
a nationwide take-back program. 
(C) The findings and recommendations 
submitted to the Director by the Administrator 
of the Environmental Protection Agency under 
subsection (b)(2). 
(b) ENVIRONMENTAL STUDY.— 
(1) STUDY REQUIRED.—The Administrator of 
the Environmental Protection Agency shall conduct 
a study identifying the environmental impacts of 
current prescription drug disposal programs and 
methods. 
VerDate Aug 31 2005 
22:28 May 09, 2007
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2223.IH
H2223
pwalker on PROD1PC71 with BILLS
(2) REPORT.—Not later than 6 months after 
the date of the enactment of this Act, the Adminis-
trator shall submit to the Director of the Office of 
National Drug Control Policy a report on the find-
ings of the study conducted under paragraph (1), 
with such recommendations as the Administrator 
considers appropriate. 
Æ 
VerDate Aug 31 2005 
22:28 May 09, 2007
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H2223.IH
H2223
pwalker on PROD1PC71 with BILLS